Literature DB >> 19880845

Treatment of anemia in chronic kidney disease--strategies based on evidence.

Philip A Marsden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19880845     DOI： 10.1056/NEJMe0909664

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

Review 1.  [The role of platelets in atherosclerosis, diabetes mellitus, and chronic kidney disease. An attempt at explaining the TREAT study results].

Authors:  Norbert Maurin
Journal:  Med Klin (Munich)       Date:  2010-05-26

2.  Conversion from epoetin alfa to darbepoetin alfa: effects on patients' hemoglobin and costs to canadian dialysis centres.

Authors:  Jessica Jordan; Joanne Breckles; Valerie Leung; Maryann Hopkins; Marisa Battistella
Journal:  Can J Hosp Pharm       Date:  2012-11

3.  Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.

Authors:  Mae Thamer; Yi Zhang; Onkar Kshirsagar; Dennis J Cotter; James S Kaufman
Journal:  Am J Kidney Dis       Date:  2014-07-08       Impact factor: 8.860

4.  The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients.

Authors:  Omar Maoujoud; Samir Ahid; Hocein Dkhissi; Zouhair Oualim; Yahia Cherrah
Journal:  Anemia       Date:  2015-12-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.